List of Excipients in Branded Drug GIMOTI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Evoke Pharma Inc	GIMOTI	metoclopramide hydrochloride	72089-307	BENZALKONIUM CHLORIDE
Evoke Pharma Inc	GIMOTI	metoclopramide hydrochloride	72089-307	CITRIC ACID MONOHYDRATE
Evoke Pharma Inc	GIMOTI	metoclopramide hydrochloride	72089-307	EDETATE DISODIUM
Evoke Pharma Inc	GIMOTI	metoclopramide hydrochloride	72089-307	SORBITOL

Gimoti Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 22, 2026

Gimoti is a metoclopramide nasal spray developed by Evoke Pharma for adult women with acute and recurrent symptoms of gastroparesis in whom delayed gastric emptying has been confirmed. Its commercial differentiation comes from nonoral delivery, not a new active ingredient. The principal excipient opportunity is to improve nasal tolerability, dose reproducibility, storage stability, and patient adherence without changing the product’s 15 mg metoclopramide dose or delivery device.

Gimoti’s strongest commercial opportunities are in patients who cannot reliably absorb or tolerate oral metoclopramide. The product faces substantial risks from the low cost of generic oral metoclopramide, the statutory limitations on chronic metoclopramide use, relatively narrow labeled population, and potential generic or alternative nasal-delivery competition.

What is Gimoti and how does it work?

Gimoti is a prescription nasal spray containing metoclopramide. Each actuation delivers 15 mg of metoclopramide in 0.1 mL of spray solution. The FDA approved Gimoti in June 2020 for adult women with acute and recurrent symptoms of gastroparesis who have failed or cannot tolerate oral metoclopramide tablets [1].

Metoclopramide is a dopamine D2-receptor antagonist with prokinetic and antiemetic activity. Gimoti is intended to bypass the gastrointestinal tract, which is relevant because gastroparesis can impair oral drug absorption and because nausea and vomiting can make oral dosing impractical.

Product attribute	Gimoti
Active ingredient	Metoclopramide
Dosage form	Nasal spray
Strength	15 mg per 0.1 mL spray
Approved population	Adult women with gastroparesis
Route	Intranasal
FDA approval	June 2020
Primary commercial differentiator	Nonoral systemic delivery
Generic-drug risk	High for oral metoclopramide; lower but material for nasal products
Biosimilar risk	Not applicable; Gimoti is a small-molecule drug

The product does not eliminate metoclopramide’s boxed warning concerning tardive dyskinesia. FDA labeling limits treatment duration to 12 weeks except in rare cases where therapeutic benefit outweighs the risk [2].

What excipients are used in Gimoti?

Gimoti uses an aqueous nasal formulation containing metoclopramide and excipients selected for pH control, tonicity, preservation, and chemical stability. The FDA-approved labeling identifies benzyl alcohol, citric acid monohydrate, edetate disodium, sodium chloride, sodium citrate dihydrate, and water for injection as inactive ingredients [2].

Excipient	Likely formulation function	Commercial or technical relevance
Benzyl alcohol	Preservative	Supports multidose-container microbiological control; raises tolerability and pediatric-exposure concerns
Citric acid monohydrate	Acidifying and buffering agent	Controls pH and may support metoclopramide stability
Sodium citrate dihydrate	Buffer component	Helps maintain formulation pH during storage and use
Edetate disodium	Chelating agent	Binds trace metals that can catalyze degradation
Sodium chloride	Tonicity modifier	Helps approximate nasal-fluid osmolality
Water for injection	Vehicle	Provides a sterile aqueous medium

The formulation strategy is commercially important because intranasal products must balance several competing requirements. A solution must remain chemically stable, avoid excessive nasal irritation, preserve dose uniformity across the life of the container, and provide a consistent plume or spray pattern.

The formulation is not an interchangeable substitute for an oral tablet based solely on the active ingredient. A competing nasal product would need to demonstrate acceptable spray performance, delivered dose, stability, microbial quality, local tolerability, and systemic exposure.

How does Gimoti’s excipient strategy support product performance?

pH and nasal tolerability

Nasal formulations are generally designed around a pH range that supports drug stability while limiting burning, irritation, and mucociliary disruption. The citrate system in Gimoti provides pH control. A competing formulation could seek a different buffer system, but any change would require evidence that the revised pH does not alter absorption or local tolerability.

Potential development alternatives include phosphate, acetate, or lower-concentration citrate buffers. These approaches may create formulation differentiation, but they also create regulatory and technical burdens. Buffer changes can affect metoclopramide solubility, preservative performance, spray-device compatibility, and stability.

Preservative system

Benzyl alcohol allows a multidose nasal container to remain microbiologically controlled during repeated use. It also creates an opportunity for reformulation.

Potential alternatives include:

• Phenoxyethanol-based preservation.
• Paraben systems.
• Benzalkonium chloride, although chronic nasal exposure can raise tolerability and mucociliary-clearance concerns.
• Preservative-free unit-dose packaging.
• A sterile single-use or dual-use delivery system.

A preservative-free Gimoti-like product could be commercially attractive for patients with nasal sensitivity or frequent use. The trade-off would be higher packaging cost, more complex manufacturing, and possible changes in patient handling.

Chelation and trace-metal control

Edetate disodium can reduce metal-catalyzed oxidation or other degradation pathways. Its presence indicates that trace-metal control is part of the stability design. A competitor could attempt to remove the chelator if stability data support the change, but that would require comparative shelf-life evidence and extractables and leachables assessment.

Tonicity

Sodium chloride helps adjust tonicity. An overly hypotonic or hypertonic spray may cause discomfort, rhinorrhea, or inconsistent retention in the nasal cavity. Tonicity is therefore a patient-experience variable, not merely a formulation specification.

Container-closure and spray-device interaction

For Gimoti, the delivery system is inseparable from the excipient strategy. The device must deliver approximately 0.1 mL per actuation and maintain dose uniformity after priming, repeated use, storage, and transport.

Critical testing includes:

• Delivered-volume uniformity.
• Droplet-size distribution.
• Spray-pattern geometry.
• Priming and repriming performance.
• Container orientation effects.
• Residual volume.
• Extractables and leachables.
• Microbial integrity.
• In-use stability.

A formulation that matches Gimoti’s excipient composition but uses a materially different device could have a different absorption profile and may require a separate clinical bridge.

What formulations are protected by Gimoti-related intellectual property?

Gimoti’s defensible intellectual-property position is likely concentrated in the combination of metoclopramide, intranasal delivery, formulation parameters, dosing, and device performance rather than in the metoclopramide molecule itself.

Potential claim categories include:

1. Intranasal metoclopramide compositions.
2. Specific concentration or dose ranges.
3. Buffered aqueous solutions.
4. Preservative-containing multidose systems.
5. Spray devices configured to deliver a defined volume.
6. Methods of treating gastroparesis with intranasal metoclopramide.
7. Pharmacokinetic or administration regimens designed to bypass impaired gastric emptying.

The commercial significance is that a generic manufacturer may be able to avoid a formulation claim by changing the buffer, preservative, concentration, device, or packaging. That does not remove regulatory requirements. It may, however, reduce literal infringement risk.

Public product materials identify Gimoti as an FDA-approved nasal formulation and indicate patent protection associated with the product. Current patent numbers, Orange Book listings, expiration dates, and pediatric exclusivity should be checked against the current FDA Orange Book and USPTO records before a launch or licensing decision [3][4].

When does Gimoti lose exclusivity?

Gimoti does not have composition-of-matter exclusivity for metoclopramide. Its exclusivity value depends on regulatory exclusivity, listed patents, formulation claims, method-of-use claims, and the difficulty of developing an equivalent nasal product.

Exclusivity category	Gimoti relevance
New chemical entity exclusivity	Not available because metoclopramide is an established active ingredient
Orphan-drug exclusivity	Not identified for Gimoti
New clinical investigation exclusivity	May apply only if the FDA-approved product qualifies under the relevant statutory provisions
Pediatric exclusivity	No public basis is assumed without a specific FDA grant
Patent exclusivity	Potentially material for nasal formulation, device, and use claims
Generic substitution	Oral metoclopramide is not automatically substitutable for Gimoti

The main loss-of-exclusivity event would be approval of an ANDA or 505(b)(2) product that successfully addresses Gimoti’s listed patents and regulatory requirements. A nasal metoclopramide product could compete without being therapeutically interchangeable with an oral tablet.

What is the Orange Book status of Gimoti?

Gimoti is an FDA-approved small-molecule drug and is therefore potentially eligible for Orange Book patent listing. Relevant listings may cover the drug product, formulation, method of use, or delivery system. The Orange Book, rather than promotional or investor materials, is the controlling public source for listed patent information [3].

A prospective generic applicant would evaluate:

• Paragraph I certification if no relevant patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification if the applicant accepts approval after patent expiration.
• Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing could trigger patent litigation under the Hatch-Waxman Act. If the NDA holder receives timely notice, an action filed within the statutory period may create a 30-month stay of ANDA approval, subject to court and regulatory outcomes [5].

Which companies are challenging Gimoti?

The most direct potential challengers are generic-drug manufacturers with nasal-device, sterile-liquid, and combination-product capabilities. Likely strategic categories include:

• Large generic companies with established ANDA operations.
• Specialty pharmaceutical companies focused on gastroenterology.
• 505(b)(2) developers pursuing differentiated nasal metoclopramide.
• Contract development and manufacturing organizations with nasal-spray platforms.

A conventional oral-metoclopramide manufacturer is not automatically a direct Gimoti competitor. The commercial barrier is the nasal product itself, including device qualification and clinical bridging.

No biosimilar competition is relevant because metoclopramide is a synthetic small molecule, not a biologic. The applicable competitive pathways are ANDA, 505(b)(2), or a new NDA.

What generic entry risks exist for Gimoti?

Gimoti faces four principal generic-entry risks.

Reformulated nasal metoclopramide

A competitor could develop a nasal formulation with a different preservative, buffer, concentration, or device. This is the most direct threat because it would target Gimoti’s delivery advantage.

505(b)(2) competition

A 505(b)(2) applicant could rely partly on existing metoclopramide data while seeking a new nasal formulation, delivery device, or dosing regimen. This pathway may be commercially attractive when the product differs from Gimoti but still relies on established pharmacology.

Oral generic substitution pressure

Generic oral metoclopramide is inexpensive and widely available. Prescribers and payers may reserve Gimoti for patients with vomiting, impaired oral absorption, or inadequate oral response. This limits pricing power.

Alternative gastroparesis therapies

The product competes with dietary management, antiemetics, other prokinetic approaches, gastric electrical stimulation, and investigational agents. Any therapy that improves symptoms without metoclopramide’s boxed-warning concerns could reduce the addressable market.

How strong is the Gimoti patent estate?

The patent estate is strongest where the claims capture the complete product architecture: metoclopramide concentration, nasal delivery, formulation chemistry, dose delivery, and treatment of a defined gastroparesis population.

Its relative weaknesses are structural:

• Metoclopramide is an old active ingredient.
• Oral and injectable metoclopramide products are generic.
• Formulation-around strategies may be available.
• Method-of-use claims may face limitations if the claimed treatment overlaps established metoclopramide use.
• Device and formulation claims can be challenged on obviousness, enablement, written description, or noninfringement grounds.

Patent strength should therefore be assessed claim by claim. A broad composition claim covering any intranasal metoclopramide product would provide stronger protection than a narrow claim requiring a particular buffer, preservative, pH, or spray volume.

What excipient-based commercial opportunities exist?

Preservative-free nasal metoclopramide

A preservative-free product in unit-dose packaging could target patients with nasal irritation or chronic sensitivity. It could also support premium positioning, although its use would need to remain consistent with metoclopramide’s labeled treatment-duration restrictions.

Improved nasal tolerability

A lower-irritation formulation could use a revised buffer, lower excipient burden, or optimized tonicity. Clinical value would depend on demonstrable improvements in burning, congestion, rhinorrhea, and treatment persistence.

Higher-use-convenience packaging

Opportunities include:

• Smaller portable devices.
• Fewer priming steps.
• Dose counters.
• Improved cap and contamination control.
• Unit-dose packaging for episodic attacks.
• Patient feedback mechanisms confirming actuation.

Extended stability

A formulation with longer room-temperature stability or reduced sensitivity to temperature excursions could improve specialty-pharmacy distribution and reduce product waste.

Payer-oriented combination strategy

Evoke or a licensee could support coverage by positioning Gimoti for patients with documented delayed gastric emptying, oral-treatment failure, or inability to retain oral medication. The strongest reimbursement case is clinical utility in a defined subgroup, not simple convenience.

International licensing

The product may have licensing potential in markets with recognized gastroparesis populations and specialty-prescription channels. Geographic expansion would require country-specific review of nasal-drug regulation, metoclopramide warnings, device requirements, and reimbursement. The commercial opportunity is greater where oral absorption failure is recognized as a treatment problem and specialty pharmacies can manage distribution.

What litigation and settlement issues affect Gimoti?

A Paragraph IV challenge could produce patent litigation involving formulation, device, or method-of-use claims. Settlement structures could include:

• A licensed generic entry date.
• A royalty-bearing authorized generic.
• Restrictions on a competing device configuration.
• A covenant not to sue for a narrow formulation.
• Geographic or indication-specific launch terms.

The economic value of settlement depends on remaining patent life, the probability of claim survival, the generic’s expected launch date, and the size of the reimbursed market. A settlement that permits early entry may preserve some branded sales but materially reduce price and formulary control.

How does Gimoti compare with oral metoclopramide?

Factor	Gimoti	Oral metoclopramide
Absorption route	Nasal	Gastrointestinal
Use when vomiting is present	More practical	May be impractical
Cost position	Branded specialty product	Generic, low-cost
Device complexity	High	Low
Formulation barrier	Nasal spray and sterile liquid	Conventional tablet or solution
Patient selection	Narrower, labeled gastroparesis population	Broader historical use
Patent differentiation	Formulation, device, use	Limited for old active ingredient
Main advantage	Bypasses gastric delivery	Price and availability

Gimoti’s commercial case depends on clinical situations where oral delivery is unreliable. It is unlikely to displace oral metoclopramide across the entire market.

Key Takeaways

• Gimoti is a 15 mg metoclopramide nasal spray approved for adult women with gastroparesis.
• Its excipient system uses benzyl alcohol, citrate buffering, sodium chloride, edetate disodium, and water for injection.
• The main formulation opportunities are preservative-free delivery, improved nasal tolerability, longer stability, and easier device operation.
• Gimoti has no biosimilar risk because metoclopramide is a small molecule.
• Generic risk is concentrated in nasal formulations and 505(b)(2) products, while oral generic metoclopramide creates persistent pricing pressure.
• Patent value is likely greatest in claims covering the integrated formulation, spray device, dose, and method of use.
• Commercial growth depends on targeting patients who cannot reliably use oral metoclopramide rather than competing solely on convenience.
• Orange Book entries, patent expiration dates, and Paragraph IV activity require live review before a transaction, launch decision, or litigation assessment.

FAQs

Can a competitor copy Gimoti’s excipients?

A competitor may be able to develop a different excipient system, but it must establish stability, spray performance, microbial quality, local tolerability, and systemic exposure. Changing excipients may reduce patent-infringement risk while creating new regulatory requirements.

Is benzyl alcohol the main differentiating excipient in Gimoti?

No. Benzyl alcohol is commercially relevant because it supports multidose preservation, but Gimoti’s differentiation comes from the complete nasal formulation and delivery system rather than one excipient.

Could a preservative-free Gimoti competitor obtain FDA approval?

Yes. A preservative-free product could pursue an ANDA, 505(b)(2), or NDA pathway depending on its formulation, device, clinical reliance, and relationship to the reference product. Packaging and microbial-control requirements would be significant.

Does Gimoti qualify for automatic substitution with oral metoclopramide?

No. A nasal spray and an oral tablet have different routes, delivery systems, and product characteristics. Pharmacy substitution depends on FDA-equivalence determinations and applicable state law.

What is the most valuable licensing asset associated with Gimoti?

The most valuable asset is the integrated nasal-delivery platform, especially if supported by enforceable formulation and device claims, reliable clinical performance, specialty-pharmacy distribution, and reimbursement in patients unable to use oral therapy.

References

1. U.S. Food and Drug Administration. (2020). FDA approves nasal spray for treatment of gastroparesis symptoms in adult women. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024). Gimoti (metoclopramide) nasal spray prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. United States Patent and Trademark Office. (2025). Patent Center. https://patentcenter.uspto.gov
5. U.S. Food and Drug Administration. (2024). Generic drug user fee amendments and ANDA patent certifications. https://www.fda.gov